Tarsus Pharmaceuticals, Inc. Stock Price, News & Analysis

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its upcoming participation in the Barclays 27th Annual Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Tuesday, March 11th at 8:00 a.m. / 11:00 a.m. ET.

Interested parties can access a live webcast of the presentation through the events section of the Tarsus website. A replay of the session will be made available within 48 hours and will remain accessible for a time on the company's website.

Tarsus Pharmaceuticals reported strong financial results for Q4 and full-year 2024, with XDEMVY® generating $66.4 million in Q4 and $180.1 million in full-year net product sales during its first full year of launch. The company dispensed over 58,500 bottles in Q4 and 163,000 bottles throughout 2024.

Key achievements include establishing broad Eye Care Professional utilization across more than 15,000 target ECPs and securing commercial, Medicare, and Medicaid reimbursement covering over 90% of lives. Tarsus launched a Direct-To-Consumer campaign on streaming platforms in Q4 2024 and began network television trials in January 2025.

The company presented groundbreaking data showing XDEMVY is the first pharmacologic treatment demonstrating functional improvements in Meibomian Gland Disease. Tarsus continues advancing its pipeline, including TP-04 for Ocular Rosacea with a Phase 2 study planned for H2 2025, and TP-05 for Lyme disease prevention.

As of December 31, 2024, Tarsus had $291.4 million in cash, cash equivalents, and marketable securities, with a net loss of $23.1 million for Q4 and $115.6 million for the full year.

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced it will host a live webcast on Tuesday, February 25, 2025, at 5:00 a.m. PT / 8:00 a.m. ET to present its fourth quarter and full-year 2024 financial results along with a corporate update. The webcast will be available for participants to access online, and a recorded version will be posted on the company's website shortly after the event, remaining accessible for approximately 90 days.

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its management team's upcoming participation in two major investor conferences in February 2025. The company will engage in fireside chats at:

• The Guggenheim SMID Cap Biotech Conference on Thursday, February 6th, at 6:00 a.m. PT / 9:00 a.m. ET

• The Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12th, at 7:00 a.m. PT / 10:00 a.m. ET

Interested parties can access a live webcast through the events section of the Tarsus website. Replay recordings will be made available within 48 hours of each event and will remain accessible for a time.

Tarsus Pharmaceuticals (NASDAQ: TARS) provided its 2025 strategic update, highlighting strong performance of XDEMVY and new development plans. The company delivered over 104,000 XDEMVY bottles in the first nine months of 2024, generating more than $113 million in net product sales. More than 13,000 Eye Care Professionals prescribed XDEMVY, with over 70% writing multiple prescriptions.

The company announced plans to advance TP-04 for Ocular Rosacea treatment, a condition affecting 15-18 million Americans with no FDA-approved therapy. A Phase 2 study is planned for second half of 2025. The company expanded its sales force with 50 new representatives in Q3 2024 and launched its first direct-to-consumer TV campaign in January 2025. Insurance coverage now extends to over 80% of lives with a gross-to-net discount in the low 40s.

Tarsus Pharmaceuticals (NASDAQ: TARS) reported Q3 2024 financial results, highlighting $48.1 million in XDEMVY® net product sales, an 18% increase over Q2 2024. The company delivered over 41,400 bottles to patients and expanded coverage to more than 80% of covered lives. Q3 net loss was $23.4 million, improving from $39.1 million in Q3 2023. The company maintains a strong cash position of $317.0 million as of September 30, 2024. New clinical data showed significant improvements in Meibomian Gland Disease measures and patient symptoms.

Tarsus Pharmaceuticals (NASDAQ: TARS) has appointed Dr. Kate Goodrich, current Chief Medical Officer of Humana, to its Board of Directors. Dr. Goodrich brings over two decades of experience in healthcare innovation and value-based initiatives. As Humana's CMO, she leads clinical operations, healthcare research, and health equity initiatives. Previously, she served as CMO at the Centers for Medicare and Medicaid Services (CMS), where she directed the Center for Clinical Standards and Quality. Dr. Goodrich continues her role as a practicing hospitalist and professor at George Washington University Medical Center while serving on multiple healthcare boards.

Tarsus Pharmaceuticals (NASDAQ: TARS) has scheduled its third quarter 2024 financial results announcement and corporate update for Wednesday, November 13, 2024, at 1:30 p.m. PT / 4:30 p.m. ET. The company will host a live webcast of the event, which will be archived on their website for approximately 90 days following the presentation.

Tarsus Pharmaceuticals (NASDAQ: TARS) has appointed Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. Dr. Yeu, who previously served as Chief Medical Advisor since 2020 and Board member since 2021, will lead the company's new Medical Organization. In her role, she will oversee medical affairs and pharmacovigilance teams, including evidence generation, medical education, and patient safety. Dr. Yeu will maintain her clinical practice at Virginia Eye Consultants while serving as CMO, bringing over two decades of ophthalmology experience to the position.